Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have spe…
Biotechnology
US, Boston [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -10.09 | 84.18 | 93.63 | |
| Graham Fair Price | 9.21 | 82.96 | 75.96 | |
| PEG | -57.23 | 1.86 | -4.34 | |
| Price/Book | -1.85 | 5.85 | 5.96 | |
| Price/Cash Flow | -88.41 | 102.60 | 884.86 | |
| Prices/Earnings | -8.78 | 24.68 | 27.06 | |
| Price/Sales | -2.99 | 40.40 | 41.65 | |
| Price/FCF | -88.41 | 102.60 | 884.86 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 2.19 | 0.87 | 0.85 | |
| Operating Margin | 11.01 | 0.42 | 0.38 | |
| ROA | 7.87 | 0.05 | 0.04 | |
| ROE | 0.06 | 0.06 | 7.59 | |
| ROIC | 0.04 | 0.05 | 15.15 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.11 | 0.09 | 25.96 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.08 | 0.18 | 141.94 | |
| EPS QOQ | -0.06 | 0.13 | 113.30 | |
| FCF QOQ | -0.90 | 7.93 | 777.71 | |
| Revenue QOQ | 0.01 | 0.07 | 388.88 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 180.68 | 213.60 | 18.22 | |
| Days Sales Outstanding (DSO) | 55.89 | 60.06 | 7.46 | |
| Inventory Turnover | 0.50 | 0.42 | -15.41 | |
| Debt/Capitalization | 0.04 | 0.04 | -14.85 | |
| Quick Ratio | 3.60 | 3.15 | -12.54 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 68.22 | 71.83 | 5.29 | |
| Cash | 43.54 | 39.39 | -9.53 | |
| Capex | -0.45 | -0.96 | -113.54 | |
| Free Cash Flow | 0.46 | 4.10 | 791.27 | |
| Revenue | 9.77 | 10.41 | 6.53 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad